How will new AI laws impact medical marketing? A pharma consultant weighs in.

Regulations governing AI are more than likely on their way – but a lot of unknowns remain. Some might say too many unknowns remain, which isn’t great for business.

While clear, comprehensive regulations for AI are widely expected – and requested – by nearly every sector of the economy, there’s plenty we don’t know. 

That said, business leaders can not and will not operate in the dark. 

Executives in our orbit, whether leading drug manufacturers, major medical marketing agencies or health media companies, require at least a sense of what’s on the horizon.

This week, pharma editor Lecia Bushak speaks with Darshan Kulkarni, a pharma regulatory consultant and founding partner at his namesake law firm. Their conversation explores the potential of new laws and regulations around AI use cases in medical marketing, such as digital avatars.

And for our Trends segment, we’re talking about Bayer’s lawsuit against Johnson & Johnson for its marketing practices around a prostate cancer drug. Plus, we are graced with a dramatic reading of Steve Madden’s satirical FDA Untitled Letter to ESPN over their faux pharma ad for March Madness.
 

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.